Literature DB >> 23526495

Nilotinib treatment-associated cerebrovascular disease and stroke.

Elizabeth A Coon, Nicholas L Zalewski, Ernest Matthew Hoffman, Ayalew Tefferi, Kelly D Flemming.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23526495     DOI： 10.1002/ajh.23442

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  16 in total

Review 1.  An update on cardio-oncology.

Authors:  Joerg Herrmann; Amir Lerman
Journal:  Trends Cardiovasc Med       Date:  2014-07-22       Impact factor: 6.677

Review 2.  Role of inflammation and oxidative stress in chemotherapy-induced neurotoxicity.

Authors:  Pooja Gupta; Tavneet Kaur Makkar; Lavisha Goel; Monika Pahuja
Journal:  Immunol Res       Date:  2022-07-20       Impact factor: 4.505

Review 3.  Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.

Authors:  Joerg Herrmann; Eric H Yang; Cezar A Iliescu; Mehmet Cilingiroglu; Konstantinos Charitakis; Abdul Hakeem; Konstantinos Toutouzas; Massoud A Leesar; Cindy L Grines; Konstantinos Marmagkiolis
Journal:  Circulation       Date:  2016-03-29       Impact factor: 29.690

4.  Neurological complications of new chemotherapy agents.

Authors:  Alicia M Zukas; David Schiff
Journal:  Neuro Oncol       Date:  2018-01-10       Impact factor: 12.300

5.  Tyrosine kinase inhibitor induced rapidly progressive vasculopathy after intracranial stent placement.

Authors:  Ching-Jen Chen; Brian J Sorace; Aria Shakeri; Min S Park; Andrew M Southerland; Bradford B Worrall; M Yashar S Kalani
Journal:  BMJ Case Rep       Date:  2018-04-03

Review 6.  Common Vascular Toxicities of Cancer Therapies.

Authors:  Joerg Herrmann
Journal:  Cardiol Clin       Date:  2019-08-26       Impact factor: 2.213

7.  Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.

Authors:  Tomohiko Ozaki; Hajime Nakamura; Nobuyuki Izutsu; Hiroaki Masaie; Jun Ishikawa; Manabu Kinoshita
Journal:  Interv Neuroradiol       Date:  2017-06-05       Impact factor: 1.610

8.  Nilotinib as a risk factor for ischaemic stroke: A series of three cases.

Authors:  J B Gómez-Galván; S Borrego; N Tovar; L Llull
Journal:  Neurologia       Date:  2016-01-06       Impact factor: 3.109

9.  Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia.

Authors:  Delphine Rea; Tristan Mirault; Thomas Cluzeau; Jean-François Gautier; François Guilhot; Hervé Dombret; Emmanuel Messas
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

10.  Nilotinib treatment-associated accelerated atherosclerosis: when is the risk justified?

Authors:  A Tefferi
Journal:  Leukemia       Date:  2013-04-22       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.